Coya Therapeutics (COYA) EBITDA Margin (2023 - 2026)
Coya Therapeutics' EBITDA Margin came in at -2889.98% for Q2 2026, up 1026.31 percentage points from -3916.29% a year earlier and up 151.03 percentage points from the prior quarter.
Powered by 
Analysis
Coya Therapeutics (COYA) EBITDA Margin (2023 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Coya Therapeutics reported EBITDA Margin of -288.46%, up 5047.37 percentage points year-over-year; for FY2025, it was -283.52%, up 201.06 percentage points from FY2024.
- Going back by year, EBITDA Margin was -484.58% in FY2024 (-353.36 pp) and -131.22% in FY2023.
- The five-year range for quarterly EBITDA Margin is -208681.10% (Q4 2024) to 30.36% (Q4 2023).
- Year-over-year, EBITDA Margin increased in three of the last six quarters, with an average year-over-year change of -283.62 percentage points.
- Business Quant data shows COYA's EBITDA Margin at -3041.01% (Q1 2026), -152.12% (Q4 2025) and -68.07% (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 42.49% |
| 10 | Coya Therapeutics | 74.13 Mn | -102.42 Mn | - | -4,675.01% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -4,675.01% |
| Jun 30, 2026 | -2,889.98% |
| Mar 31, 2026 | -3,041.01% |
| Dec 31, 2025 | -152.12% |
| Sep 30, 2025 | -68.07% |
| Jun 30, 2025 | -3,916.29% |
| Mar 31, 2025 | -2,974.24% |
| Dec 31, 2024 | -208,681.10% |
| Jun 30, 2024 | -94.28% |
| Mar 31, 2024 | -4,317.45% |
| Dec 31, 2023 | 30.36% |
API Access
Coya Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=COYA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "COYA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=COYA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();